Cas:68774-48-1 2,5-Anhydro-1-O-triphenylmethyl-D-mannitol manufacturer & supplier

We serve Chemical Name:2,5-Anhydro-1-O-triphenylmethyl-D-mannitol CAS:68774-48-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,5-Anhydro-1-O-triphenylmethyl-D-mannitol

Chemical Name:2,5-Anhydro-1-O-triphenylmethyl-D-mannitol
CAS.NO:68774-48-1
Synonyms:2,5-anhydro-1-O-trityl-D-mannitol
Molecular Formula:C25H26O5
Molecular Weight:406.47100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:79.15000
Exact Mass:406.17800
LogP:2.47660

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,5-anhydro-1-O-trityl-D-mannitol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,5-anhydro-1-O-trityl-D-mannitol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,5-anhydro-1-O-trityl-D-mannitol Use and application,2,5-anhydro-1-O-trityl-D-mannitol technical grade,usp/ep/jp grade.


Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. 2,5-Anhydro-1-O-triphenylmethyl-D-mannitol manufacturer We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally. 2,5-Anhydro-1-O-triphenylmethyl-D-mannitol supplier The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry. 2,5-Anhydro-1-O-triphenylmethyl-D-mannitol vendor The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 2,5-Anhydro-1-O-triphenylmethyl-D-mannitol factory The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.